8-oxabicyclo[3.2.1]octan-3-ol | 343963-51-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 8-oxabicyclo[3.2.1]octan-3-ol
• 英文别名: (1R,3R,5S)-8-oxabicyclo[3.2.1]octan-3-ol
• CAS: 343963-51-9
• 化学式: C₇H₁₂O₂
• 分子量: 128.171
• InChiKey: CSGTZGMKSPXFEQ-KVSKUHBBSA-N

物化性质

• 沸点：
  253.8±8.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.69
• 重原子数：
  9.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.46
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  8-oxabicyclo[3.2.1]octan-3-ol 在 sodium azide 、 palladium on activated charcoal 、 氢气 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  WO2024097629A1

  摘要：

  公开号：
• 作为产物：
  描述：

  8-氧杂双环[3.2.1]辛烷-3-酮 在 platinum(IV) oxide 氢气 作用下， 以 甲醇 为溶剂， 以80%的产率得到8-oxabicyclo[3.2.1]octan-3-ol
  参考文献：
  名称：

  Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter

  摘要：

  6-Methoxylated and 8-oxygenated benztropines were prepared and evaluated for their DAT and SERT activity (binding and uptake inhibition). Methoxylation at the two-carbon bridge of benztropine produced a novel class of potent and selective DAT ligands. An interesting enantioselectivity was also observed for this new class of chiral benztropines. The inactivity of the 8-oxygenated analogues seems to point out that, unlike cocaine and its analogues, interactions of benztropine ligands with DAT may be strongly governed by the nitrogen atom. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00068-3

文献信息

• [EN] THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF<br/>[FR] DÉRIVÉS DE THIÉNOPYRIMIDINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS D'ACC ET LEURS UTILISATIONS
  申请人：GILEAD SCIENCES INC

  公开号：WO2021030142A1

  公开（公告）日：2021-02-18

  The present disclosure relates generally to compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disase (NAFLD) and non-alcoholic steatohepatitis (NASH).

  本公开涉及一般与结合乙酰辅酶A羧化酶（ACC）并作为ACC的抑制剂的化合物有关。此外，本公开还涉及利用这些化合物制备药物以治疗通过结合ACC引起的疾病和/或状况，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）等肝病。
• Functional characterization of recombinant hyoscyamine 6β-hydroxylase from Atropa belladonna
  作者：Jing Li、Marco J. van Belkum、John C. Vederas

  DOI：10.1016/j.bmc.2012.05.042

  日期：2012.7

  (-)-Hyoscyamine, the enantiomerically pure form of atropine, and its derivative scopolamine are tropane alkaloids that are extensively used in medicine. Hyoscyamine 6 beta-hydroxylase (H6H, EC 1.14.11.11), a monomeric alpha-ketoglutarate dependent dioxygenase, converts (-)-hyoscyamine to its 6,7-epoxy derivative, scopolamine, in two sequential steps. In this study, H6H of Atropa belladonna (AbH6H) was cloned, heterologously expressed in Escherichia coli, purified and characterized. The catalytic efficiency of AbH6H, especially for the second oxidation, was found to be low, and this may be one of the reasons why Atropa belladonna produces less scopolamine than other species in the same family. 6,7-Dehydrohyoscyamine, a potential precursor for the last step of epoxidation, was shown not to be an obligatory intermediate in the biosynthesis of scopolamine using purified AbH6H with an in vitro O-18 labeling experiment. Moreover, the nitrogen atom in the tropane ring of (-)-hyoscyamine was found to play an important role in substrate recognition. (C) 2012 Elsevier Ltd. All rights reserved.

  (-)-东莨菪碱是阿托品的旋光纯形式，而其衍生物天仙子胺是托品烷生物碱的一种，在药物中有着广泛应用。东莨菪碱6β-羟化酶（H6H，EC 1.14.11.11），一种单体α-酮戊二酸依赖型双加氧酶，通过两步连续反应将(-)-东莨菪碱转化为其中间体6,7-环氧衍生物——天仙子胺。本研究中，我们对毒蕈（Atropa belladonna）来源的H6H（AbH6H）进行了克隆、异源表达、纯化及功能表征。实验发现，AbH6H的催化效率较低，尤其是在第二次氧化反应中，这可能是毒蕈相比同属其他物种产生更少天仙子胺的原因之一。潜在的最终环氧化前体——6,7-脱氢东莨菪碱，通过体外O-18标记实验，证实其并非天仙子胺生物合成的必要中间体。此外，托品烷环中的氮原子在底物识别过程中扮演了关键角色。版权 © 2012 Elsevier Ltd. 保留所有权利。
• [EN] DNA-DEPENDENT PROTEIN KINASE INHIBITOR<br/>[FR] INHIBITEUR DE PROTÉINE KINASE DÉPENDANTE DE L'ADN
  申请人：DIZAL JIANGSU PHARMACEUTICAL CO LTD

  公开号：WO2020238900A1

  公开（公告）日：2020-12-03

  Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as DNA-PK inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat DNA-PK related disorder (e.g., cancer).

  本文披露了式（I）的化合物及其药学上可接受的盐，这些化合物可用作DNA-PK抑制剂。还披露了包含一种或多种式（I）化合物的药物组合物，以及使用这些化合物或组合物来治疗DNA-PK相关疾病（例如癌症）的方法。
• Thienopyrimidine derivatives as ACC inhibitors and uses thereof
  申请人：Gilead Sciences, Inc.

  公开号：US11352371B2

  公开（公告）日：2022-06-07

  The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

  本公开一般涉及与乙酰-CoA 羧化酶（ACC）结合并作为 ACC 抑制剂的噻吩嘧啶化合物。本公开进一步涉及噻吩嘧啶化合物用于制备通过与 ACC 结合治疗疾病和/或病症的药物，包括肝脏疾病，如非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）。
• THIENOPYRIMIDINE DERIVATIVES AS ACC INHIBITORS AND USES THEREOF
  申请人：GILEAD SCIENCES, INC.

  公开号：EP4010344A1

  公开（公告）日：2022-06-15